Illinois, Chicago (PRWEB) August 13, 2015
This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects.
Complete report with TOC is available at http://www.rnrmarketresearch.com/osteoarthritis-pipeline-review-h1-2015-market-report.html.
The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this report are A. Menarini Industrie Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Addex Therapeutics Ltd, Ampio Pharmaceuticals, Amura Holdings Limited, Arcarios BV, Asklepios BioPharmaceutical, Inc., Astellas Pharma Inc., Biomet Biologics, LLC, Biopharm GmbH, Can-Fite BioPharma Ltd., Cardax Pharmaceuticals, Inc., Celgene Corporation, Cellceutix Corporation, Cellular Biomedicine Group, Inc., Celsus Therapeutics Plc, Chong Kun Dang Pharmaceutical Corp., Eli Lilly and Company, Galapagos NV, GeneFrontier Corporation, Genequine Biotherapeutics GmbH, GlaxoSmithKline Plc, IMMD Inc., IntelliCell BioSciences Inc., Jeil Pharmaceutical Co., Ltd., Jenrin Discovery, Inc., K-Stemcell Co., Ltd., Laila Pharmaceuticals Pvt. Ltd., Levolta Pharmaceuticals, Inc., Medivir AB, Merck KGaA, Mesoblast Limited, Mor Research Application Ltd, NicOx S.A., Nordic Bioscience A/S, Novartis AG, Ocata Therapeutics, Inc., Omeros Corporation, Ono Pharmaceutical Co., Ltd., OrthoCyte Corporation, Osteologix Holdings Plc, Pharmalink AB, PolyNovo Limited, ReqMed Company, Ltd., Rottapharm SpA, Sanofi, Seikagaku Corporation, Shanghai Fudan-Zhangjiang Bio-pharmaceutical Co., Ltd., STELIS Biopharma Pvt. Ltd., Stempeutics Research Private Limited, Symic Biomedical, Inc., Takeda Pharmaceutical Company Limited, TissueGene, Inc., TOKUHON Corporation, Upsher-Smith Laboratories, Inc., Yooyoung Pharmaceutical Co., Ltd., Yuhan Corporation and Yungjin Pharm Ind. Co., Ltd.
Order a purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=403551. (This is a premium report priced at US$2000 for a single user License.)
List of Figures:-
Number of Products under Development for Osteoarthritis, H1 2015 22
Number of Products under Development for Osteoarthritis - Comparative Analysis, H1 2015 23
Number of Products under Development by Companies, H1 2015 24
Number of Products under Investigation by Universities/Institutes, H1 2015 31
Comparative Analysis by Late Stage Development, H1 2015 33
Comparative Analysis by Clinical Stage Development, H1 2015 34
Comparative Analysis by Early Stage Products, H1 2015 35
Assessment by Monotherapy Products, H1 2015 103
Assessment by Combination Products, H1 2015 104
Number of Products by Top 10 Targets, H1 2015 105
Number of Products by Stage and Top 10 Targets, H1 2015 106
Number of Products by Top 10 Mechanism of Actions, H1 2015 111
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 112
Number of Products by Top 10 Routes of Administration, H1 2015 116
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 117
Number of Products by Top 10 Molecule Types, H1 2015 119
Number of Products by Stage and Top 10 Molecule Types, H1 2015 120
Scope of this report:
The report provides a snapshot of the global therapeutic landscape of Osteoarthritis. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects. The report summarizes all the dormant and discontinued pipeline projects. A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages. A detailed assessment of monotherapy and combination therapy pipeline projects. Coverage of the Osteoarthritis pipeline on the basis of target, MoA, route of administration and molecule type. Latest news and deals relating related to pipeline products.
Table of Contents:-
- Osteoarthritis Overview
- Therapeutics Development
- Osteoarthritis - Therapeutics under Development by Companies
- Osteoarthritis - Therapeutics under Investigation by Universities/Institutes
- Osteoarthritis - Pipeline Products Glance
- Osteoarthritis - Products under Development by Companies
- Osteoarthritis - Products under Investigation by Universities/Institutes
- Osteoarthritis - Companies Involved in Therapeutics Development
- Osteoarthritis - Therapeutics Assessment
- Drug Profiles
- Osteoarthritis - Recent Pipeline Updates
- Osteoarthritis - Dormant Projects
- Osteoarthritis - Discontinued Products
- Osteoarthritis - Product Development Milestones